Regarding the results, the studies showed a reduction by 53% in disease severity (not needing intensive care),(38) 26% in length of hospital stay,(36) and from 35% to 50% in mortality rate,(36–38) reporting adverse effects in less than 4% of patients after treatment with CP in different doses and volumes associated with standard therapy for COVID-19,(36–38) as shown in table 2. The gene discussed is CP; the disease is COVID-19.